State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma
作者： Bertrand Coiffier
关键词:
摘要: This article is a review of the improvement in treatment patients with diffuse large B-cell lymphoma made during last 10 years. Patients now have better outcome longer survival because two major developments: (1) increasing dose active drugs shortening time between cycles, resulting dose-dense and/or dose-intense regimens; and (2) combining rituximab chemotherapy. Both strategies were associated higher response rates, lower relapse event-free survival, to progression, overall particularly without adverse prognostic parameters. A combination dose-dense, regimens plus currently being tested for poor-risk lymphoma. However, much work has be done high-risk It may come definition genetic abnormalities specifically refractoriness
jco.org参考文章(31)
V. Diehl, A. Lister, J.A. Radford, D. Ma, P. Johnson, A. Engert, F. Reyes, C. Haioun, H. Tilly, R. Capdeville, B. Coiffier, N. Ketterer, M. Feuring Buske, Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study Blood. ,vol. 92, pp. 1927- 1932 ,(1998) , 10.1182/BLOOD.V92.6.1927
Bertrand Coiffier, Treatment of diffuse large B-cell lymphoma. Current hematology reports. ,vol. 4, pp. 7- 14 ,(2005)
M. G. Pfreundschuh, A. Ho, M. Wolf, E. Cavallin-Stahl, R. Pettengell, I. Vasova, A. Belch, J. Walewski, P.-L. Zinzani, W. Mingrone, M. Loeffler, Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study Journal of Clinical Oncology. ,vol. 23, pp. 6529- 6529 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.6529
Corinne Haioun, Eric Lepage, Christian Gisselbrecht, Gilles Salles, Bertrand Coiffier, Pauline Brice, André Bosly, Pierre Morel, Christiane Nouvel, Hervé Tilly, Pierre Lederlin, Catherine Sebban, Josette Brière, Philippe Gaulard, Félix Reyes, Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study Journal of Clinical Oncology. ,vol. 18, pp. 3025- 3030 ,(2000) , 10.1200/JCO.2000.18.16.3025
M A Shipp, D Neuberg, M Janicek, G P Canellos, L N Shulman, High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. Journal of Clinical Oncology. ,vol. 13, pp. 2916- 2923 ,(1995) , 10.1200/JCO.1995.13.12.2916
Andreas Rosenwald, George Wright, Wing C. Chan, Joseph M. Connors, Elias Campo, Richard I. Fisher, Randy D. Gascoyne, H. Konrad Muller-Hermelink, Erlend B. Smeland, Jena M. Giltnane, Elaine M. Hurt, Hong Zhao, Lauren Averett, Liming Yang, Wyndham H. Wilson, Elaine S. Jaffe, Richard Simon, Richard D. Klausner, John Powell, Patricia L. Duffey, Dan L. Longo, Timothy C. Greiner, Dennis D. Weisenburger, Warren G. Sanger, Bhavana J. Dave, James C. Lynch, Julie Vose, James O. Armitage, Emilio Montserrat, Armando López-Guillermo, Thomas M. Grogan, Thomas P. Miller, Michel LeBlanc, German Ott, Stein Kvaloy, Jan Delabie, Harald Holte, Peter Krajci, Trond Stokke, Louis M. Staudt, The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma The New England Journal of Medicine. ,vol. 346, pp. 1937- 1947 ,(2002) , 10.1056/NEJMOA012914
Bertrand Coiffier, Increasing chemotherapy intensity in aggressive lymphomas: a renewal? Journal of Clinical Oncology. ,vol. 21, pp. 2457- 2459 ,(2003) , 10.1200/JCO.2003.93.116
Douglas W. Blayney, Michael L. LeBlanc, Thomas Grogan, Ellen R. Gaynor, Robert A. Chapman, C. Harris Spiridonidis, Sarah A. Taylor, Scott I. Bearman, Thomas P. Miller, Richard I. Fisher, Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349) Journal of Clinical Oncology. ,vol. 21, pp. 2466- 2473 ,(2003) , 10.1200/JCO.2003.06.137
Wyndham H Wilson, Martin Gutierrez, Paula O'Connor, Stanley Frankel, Elaine Jaffe, Bruce A Chabner, Michael L Grossbard, The Role of Rituximab and Chemotherapy in Aggressive B-Cell Lymphoma: A Preliminary Report of Dose-Adjusted EPOCH-R Seminars in Oncology. ,vol. 29, pp. 41- 47 ,(2002) , 10.1053/SONC.2002.30151
Cynthia X. Ma, Martha Q. Lacy, John F. Rompala, Angela Dispenzieri, S. Vincent Rajkumar, Philip R. Greipp, Rafael Fonseca, Robert A. Kyle, Morie A. Gertz, Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma Blood. ,vol. 104, pp. 40- 42 ,(2004) , 10.1182/BLOOD-2003-10-3400